September 30, 2025 — Leads & Copy — GeneDx (Nasdaq: WGS) has appointed Lisa Gurry as Chief Business Officer, effective immediately, to lead the next phase of transformation and advance data and information services across biopharma, health systems, and other partners to accelerate precision medicine.
As CBO, Gurry will architect and operate strategic business operations and partnership models to unlock the full potential of GeneDx Infinity™, the largest rare disease dataset, with nearly one million exomes and genomes paired with more than seven million phenotypic datapoints. She will also oversee communications and partner on market growth strategies.
Katherine Stueland, President and CEO of GeneDx, stated that Gurry’s leadership in data commercialization, partnerships, and go-to-market execution is needed to unlock the full potential of genomic data. Gurry co-founded Truveta and has over two decades at Microsoft driving global growth strategies.
Gurry says that by combining the scale of GeneDx Infinity with the urgency of the company’s mission, GeneDx can accelerate diagnoses for families, fuel drug discovery for biopharma, and deliver data-powered value to health systems.
GeneDx (Nasdaq: WGS) is a global leader in rare disease diagnosis, transforming medicine by making genomics the starting point for health. The company brings together clinical expertise, advanced technology, and GeneDx Infinity™ to power ExomeDx and GenomeDx tests.
Contact:
[No contact information provided in the press release.]
Source: GeneDx
